Montelukast Intermediate Market Global Research Report - Forecast till 2030

Montelukast Intermediate Market: Information by Application (Asthma, Allergic Rhinitis, Bronchospasm and Urticaria) - Forecast till 2030

ID: MRFR/HC/6415-CR | May 2019 | Region: Bric | 78 Pages         

Montelukast Intermediate Market Speak to Analyst Request a Free Sample

Montelukast Intermediate Market Overview


The Montelukast Intermediate market is projected to reach USD 7.09 Million by 2030 at 4.20% CAGR during the forecast period 2022-2030.


Montelukast is a leukotriene receptor antagonist (LTRA) used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma. In addition, montelukast is indicated for the treatment of seasonal and perennial allergic rhinitis. Key factors driving the market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration along with the increasing presence of generics. On the contrary, the presence of stringent regulatory policies and the high cost of manufacturing building blocks for active pharmaceutical ingredients are likely to hinder the market growth during the forecast period.


Market Dynamics


Factors characterizing the market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from API manufacturers, and montelukast patent expiration along with the increasing presence of generics. In 2016, asthma ranked twenty third (global) and thirty-first (in low- and middle-income countries — LMICs) among the leading causes of premature mortality (YLL). The World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide every year.


Montelukast Intermediate Market Revenue, by Application, 2017 (USD Mn)  Montelukast Intermediate Market_Image


Sources: MRFR Analysis


Segmentation


The montelukast intermediate Market, by application, can be classified into three types, namely, asthma, allergic rhinitis, bronchospasm, and urticaria.


Key Players


The prominent players in the Montelukast Intermediate market are VIVAN Life Sciences, P.G. Shah & Co., Manus Aktteva Biopharma LLP and Ortin Laboratories Limited.


Some of the key strategies followed by the players operating in the Montelukast Intermediate market were innovation, product development, acquisition, and expansion.


Montelukast Intermediate Market Share, by Region, 2017 (%)  Montelukast Intermediate Market_Image


Sources: MRFR Analysis


Regional Analysis


The Montelukast Intermediate Market in the Americas is segmented into North America and Latin America.


North America is expected to dominate the market. The market growth in this region is mainly due to the presence of giant pharmaceutical companies and sophisticated healthcare infrastructure and the rising prevalence of asthma and allergic rhinitis in the US and Canada. One in 13 people is living with asthma and is more common in adult women than adult men. Around six million children under the age of 18 have asthma being more common in children than adults. Therefore, the increasing burden of asthma is fueling the demand for montelukast and is assisting in market growth.


Europe currently holds a significant share in the Montelukast Intermediate market. The factors responsible for the market growth in this region are poor air quality due to high fuel emission is increasing the incidence of asthma, allergy, and chronic obstructive pulmonary disease (COPD) in the UK, Germany, and France. The European Respiratory Society reported that, currently, about 30 Million children and adults less than 45 years old have asthma within the UK and Ireland have some of the highest rates of asthma in the world. In Germany, there are an estimated 4 Million asthmatics. In addition, an article published in the NCBI journal stated that the prevalence of allergic diseases in Europe is high.


Asia-Pacific is expected to represent a promising outlook over the forecast period due to the growing geriatric population along with the rising prevalence of respiratory diseases. According to the WHO, currently, there are about 3 Million asthmatics in Japan of whom 7% have severe, and 30% have moderate asthma. In Australia, one child out of six under the age of 16 is affected by asthma, while, India has an estimated 15 to 20 Million.


The Middle East and Africa market are projected to hold the least share in the Montelukast Intermediate market. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others.


Market Segmentation


Montelukast Intermediate Market, by Application



  • Asthma

  • Allergic Rhinitis

  • Bronchospasm

  • Urticaria


Montelukast Intermediate Market, by Region



  • North America


    • US

    • Canada




  • Europe


    • Germany

    • Russia

    • France

    • Italy

    • UK

    • Rest of Europe




  • Asia-Pacific


    • China

    • India

    • Japan

    • Rest of Asia-Pacific




  • Latin America


    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America




  • Middle East & Africa


Available Additional Customizations


Intended Audience



  • Montelukast API Manufacturer

  • Academic and Research Institutes

  • Pharmaceutical Manufacturers

  • Reference Laboratories

  • Pharmaceutical Raw Materials Suppliers

  • Montelukast Intermediate Manufacturers

  • Market Research and Consulting Firms



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The forecast period of (2022-2030) would see the Montelukast Intermediate Market grow with a CAGR of 4.20%.

The projected valuation of the Montelukast Intermediate Market is USD 7.09 Million.

The high cost of the process to manufacture building blocks can deter market growth.

The players are Manus Aktteva Biopharma LLP, P.G. Shah & Co., VIVAN Life Sciences, and Ortin Laboratories Limited.

The segments are bronchospasm, allergic rhinitis, asthma, and urticaria.